{"nctId":"NCT02899962","briefTitle":"LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris","startDateStruct":{"date":"2017-02-15","type":"ACTUAL"},"conditions":["Psoriasis Vulgaris"],"count":722,"armGroups":[{"label":"LEO 90100 aerosol foam","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: LEO 90100 aerosol foam"]},{"label":"LEO 90100 aerosol foam vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: LEO 90100 aerosol foam vehicle"]}],"interventions":[{"name":"LEO 90100 aerosol foam","otherNames":[]},{"name":"LEO 90100 aerosol foam vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"INCLUSION CRITERIA:\n\n* A clinical diagnosis of psoriasis vulgaris for at least 6 months involving the trunk and/or limbs, amenable to treatment with maximum of 100 g of trial medication per week\n* Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) involving 2-30% of the body surface area (BSA)\n* A target lesion/target location of at least 3 cm at its longest axis located on the body (i.e., not on the scalp, face or intertriginous areas), scoring at least 1 ('mild') for each of redness, thickness and scaliness, and at least 4 in total by the Investigator's Assessment of Severity of the Target Lesion/Location\n\nFor subjects participating in hypothalamic-pituitary-adrenal (HPA)-axis testing, furthermore:\n\n* An extent of psoriasis vulgaris on trunk and/or limbs of disease severity (PGA) of at least 'moderate' affecting between 10 and 30% of the body surface area (BSA) excluding psoriatic lesions of genitals and skin folds at Visit 1.\n\nEXCLUSION CRITERIA:\n\n* Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to Visit 1:\n\n  * etanercept - within 4 weeks prior to Visit 1\n  * adalimumab, infliximab - within 8 weeks prior to Visit 1\n  * ustekinumab - within 16 weeks prior to Visit 1\n  * secukinumab - within 12 weeks prior to Visit 1\n  * other products - within 4 weeks/5 half-lives prior to Visit 1 (whichever is longer)\n* Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other immunosuppressants) within 4 weeks prior to Visit 1\n* Systemic treatment with apremilast within 4 weeks prior to Visit 1\n* Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to Visit 1\n* Ultraviolet B (UVB) therapy within 2 weeks prior to Visit 1\n* Severe and/or extensive scalp psoriasis which, in the opinion of the investigator, requires treatment with potent or super-potent corticosteroids which will be prohibited during the trial\n\nFor subjects participating in HPA-axis testing, furthermore:\n\n* Antidepressive medications within 4 weeks prior to Visit 1 or during the trial. Oestrogen therapy (including contraceptives), antidepressant medications and any other medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior to baseline","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to First Relapse","description":"Time to first relapse (at least 'mild' according to the Physician's Global Assessment of disease severity \\[PGA\\]). The investigator was to grade the severity of psoriasis of the trunk and limbs using Physician's global assessment of disease severity 5-point scale: Clear = 0; Almost clear = 1; Mild = 2; Moderate = 3; Severe = 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Days in Remission During the Maintenance Phase","description":"Remission defined as 'clear' or 'almost clear' according to the PGA. The investigator was to grade using a global assessment of the disease severity of psoriasis of the trunk and limbs using the PGA 5-point scale: Clear = 0; Almost clear = 1; Mild = 2; Moderate = 3; Severe = 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.2","spread":"21.7"},{"groupId":"OG001","value":"60.8","spread":"20.1"}]}]}]},{"type":"SECONDARY","title":"Number of Relapses During the Maintenance Phase","description":"Defined as number of 4-week periods with use of once-daily rescue investigational medicinal product","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.7"},{"groupId":"OG001","value":"3.1","spread":"2.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":650},"commonTop":["Nasopharyngitis","Vitamin D deficiency","Upper respiratory tract infection","Rebound psoriasis","Back pain"]}}}